JPRN-UMIN000017177已完成2 期
Phase II study of Nab-paclitaxel plus S-1 followed by FEC as neoadjuvant chemotherapy for the operable breast cancer - Phase II study of Nab-paclitaxel plus S-1 followed by FEC as neoadjuvant chemotherapy for the operable breast cancer
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) History of hypersensitivity reaction 2) HER2 negative disease 3) Active double cancer 4) Other severe complications, such as uncontrolled diabetes mellitus, uncontrolled angina, myocardial infarction within 6 months, heart failure. 5) Severe mental disorder 6) Sever bone marrow suppression, renal dysfunction, liver dysfunction 7) Has watery diarrhea 8) Active infection or potentiality infection 9) History of hypersensitivity for albumin 10) Grade2 or grater peripheral neuropathy 11)Pregnant or lactating women, women who are capable of pregnancy, intend to get pregnant 12)Judged ineligible based on physicians' decision
研究者
相似试验
尚未招募
不适用
Phase II study of nab-paclitaxel combined with S-1 in patients with early breast cancer:A multicenter clinical trialearly breast cancerJPRN-UMIN000027216The University of Tokushima Graduate School80
已完成
不适用
A Phase I/II study of nab-Paclitaxel plus S-1 therapy in previously treated patients with refractory advanced non-small-cell lung cancerJPRN-UMIN000012966Depatment of Thoracic Oncology Osaka Medical Center for Cancer and Cardiovascular Diseases45
招募中
2 期
Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancerRefractory small-cell lung cancerJPRN-UMIN000015565Dokkyo Medical University22
已完成
2 期
PhaseII study of Nab-paclitaxel followed by EC as neoadjuvant chemotherapy for the operable breast cancerBreast cancerJPRN-UMIN000022931Rakuwakai Otowa Hospital Breast oncology department24
招募中
不适用
Phase II study of weekly Nab-paclitaxel followed by FEC as Neoadjuvant Chemotherapy for Breast CancerBreast cancerJPRN-UMIN000005979Wakayama Medical University50